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Background: Cardiovascular morbidity and mortality remains excessive in patients with chronic kidney disease. The
association of vascular changes with regulators of extraosseous calcification in this patient population is still under
investigation. The aim of the present study was to investigate the associations of the calcification inhibitor fetuin-A,
and the anti-osteoclastic factor osteoprotegerin (OPG) with vascular pathology in chronic hemodialysis patients.
Methods: In this cross-sectional study including 81 stable chronic hemodialysis patients, we measured carotid-to-femoral
pulse wave velocity (cfPWV) with applanation tonometry, reflecting arterial stiffness, and common carotid intima-media
thickness (ccIMT), a surrogate of early atherosclerosis, as well as serum levels of fetuin-A and OPG. Co-morbidities,
traditional cardiovascular risk factors, inflammatory markers and mineral-bone disease serology parameters were also
recorded.
Results: cfPWV correlated inversely with fetuin-A (r=−0.355, p=0.001) and positively with OPG (r=0.584, p<0.001). In
multilinear regression analysis including age, gender, diabetes, cardiovascular disease, hypertension, pulse pressure, LDL,
logCRP, both fetuin-A and OPG were independently associated with cfPWV (p=0.024 and p=0.041 respectively). ccIMT
was negatively associated with fetuin-A (r=−0.312, p=0.005) and positively with OPG (r=0.521, p<0.0001); however these
associations lost statistical significance after adjustment for age.
Conclusion: In chronic hemodialysis patients both fetuin-A and OPG levels are independently associated with arterial
stiffness but not with early atherosclerotic vascular changes.
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Cardiovascular pathology remains the leading cause of
morbidity and mortality in patients with chronic kidney
disease (CKD) [1]. Two types of vascular changes are
observed, atherosclerotic and arteriosclerotic [2]. Ath-
erosclerosis is associated with increase of the arterial in-
tima–media thickness (IMT), leading eventually to
luminal obstruction with consequent ischemic events,
such as myocardial infarction and stroke. Arterioscler-
osis leads to arterial stiffening and increased pulse wave
velocity (PWV) and pulse pressure, resulting in left ven-
tricular hypertrophy and reduced coronary perfusion. In* Correspondence: aikpapag@otenet.gr
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reproduction in any medium, provided the orCKD patients both atherosclerosis and arteriosclerosis
appear early and follow an accelerated course contribut-
ing to the excessive cardiovascular mortality in this pa-
tient population [3,4].
The pathogenesis of vasculopathy in end-stage renal
disease (ESRD) involves traditional risk factors of athero-
sclerosis (older age, hypertension, dyslipidemia, diabetes
mellitus), which are highly prevalent in this patient
population, but also several uremia-related risk factors
(inflammation, oxidative stress, mineral and bone disor-
ders), which are still under investigation [5].
Recent evidence suggests that vascular calcification is
a highly regulated active process, and that the pheno-
typic trans-differentiation of vascular smooth muscle
cells (VSMCs) into osteoblast-like cells is a key patho-
genetic event [5]. A variety of factors that influence thisral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mineral homeostasis and bone turnover, as well as im-
balance between promoters and inhibitors of extra-
osseous bone formation [5]. Thus it appears that there is
an interaction between bone metabolism and vascular
health, placing current understanding of vascular patho-
physiology on a bone-vascular axis [5].
Fetuin-A is a liver-derived potent systemic inhibitor of
calcification and a negative acute phase reactant [6]. Apart
from preventing calcium and phosphate precipitation in
the serum, fetuin-A protects from arterial media calcifica-
tion by inhibiting VSMC apoptosis and preventing basic
calcium particle nucleation in the extracellular matrix [7].
In hemodialysis (HD) patients, low fetuin-A levels have
been associated with severe and extensive vascular calcifi-
cation, as well as with increased all-cause and cardiovas-
cular mortality [8].
Osteoprotegerin (OPG) is a soluble member of the
tumor necrosis factor (TNF) receptor superfamily, pro-
duced by osteoblasts and vascular endothelial and
smooth muscle cells [9]. It has an anti-osteoclastic effect
being a soluble decoy receptor for the osteoclast activa-
tor RANKL (receptor activator of nuclear factor-κB lig-
and). Moreover, it appears to be an important regulator
of vascular calcification [10] and in HD patients, high
OPG levels have been associated with vascular calcifica-
tion and mortality [11].
The precise roles of fetuin-A and OPG in the develop-
ment of uremic vasculopathy are not fully elucidated
[12]. The aim of the present study was to investigate the
associations of serum fetuin-A and OPG levels with ca-
rotid to femoral PWV (cfPWV), a marker of arterioscler-
osis [13], and common carotid IMT (ccIMT), a marker




Eighty one adult patients (52 male, mean age 59.8 years,
range 22–86 years) on chronic maintenance HD for at
least three months (mean HD duration 66 months,
range 3–274 months) were included in the study. All pa-
tients were from the Dialysis Unit of the University De-
partment of Nephrology at “Hippokration” General
Hospital who consented to the protocol and entered the
study consecutively. Chronic renal failure was attributed
to glomerulonephritis in 21 cases (25.9%), diabetes
mellitus in 17 (21%), tubulointerstitial nephritis in 10
(12.3%), polycystic kidney disease in 8 (10.0%), renovas-
cular hypertension in 7 (8.6%), and was undetermined in
18 cases (22.2%). Patients were clinically stable without
active malignancy, infection, or liver disease. None of the
patients was receiving antibiotics or immunosuppressive
agents and none had a history of parathyroidectomy at thetime of the study. All patients were receiving conventional
3.5 to 4.5-h HD, three times weekly, with synthetic
(polysulphone or helixone) dialyzers, bicarbonate dialysate
and tinzaparin as standard anticoagulation. Dialysis
prescription was guided by a goal of achieving a value
of Kt/V ≥1.2, as calculated by the second-generation
Daugirdas equation. The achieved Kt/V was 1.46 ±0.21
(range 0.92 – 2.0).
The protocol conformed to the ethical guidelines of
our institution and it was approved by the Institutional
Review Board of “Hippokration” General Hospital. All
patients signed an informed consent prior to the study
entry.
Laboratory methods
Blood samples were drawn from a peripheral vein under
fasting conditions in the morning of a midweek routine
dialysis session. Serum samples were separated from
clotted blood by immediate centrifugation (1500g for 10
min), aliquoted and stored at −70°C until assay. Serum
levels of fetuin-A and OPG were measured by an
enzyme-linked immunosorbent assay (ELISA) using
commercially available standard kits (human fetuin-A
and human osteoprotegerin, BioVendor GmbH Heidel-
berg, Germany, detection limit 0.35 ng/ml and 0.10
pmol/L respectively). Serum albumin, total cholesterol,
triglycerides, HDL cholesterol, LDL cholesterol, calcium,
phosphorus and alkaline phosphatase were determined
by routine techniques using an automated analyser
(Olympus AU560, Hamburg, Germany). Levels of albu-
min were time averaged for the last six months before
inclusion in the study. Intact parathormone (iPTH)
levels were measured by radioimmunoassay (RIA).
Serum CRP levels were measured by nephelometry. The
detection limit was 3.75 mg/L and in the statistical
evaluation all values <3.75 mg/L were treated as 3 mg/L.
PWV measurements
cfPWV measurements were performed with the
SphygmoCor® (AtCor® Medical, Sydney, Australia), by
a trained operator unaware of the patient’s clinical and
laboratory parameters. The device uses a high-fidelity
applanation tonometer for transdermal pulse wave re-
cording. Each subject was examined in the supine pos-
ition during a mid-week non-dialysis day and within
one month from blood sampling. cfPWV measure-
ments were done in two steps. The first step involved
recording the carotid pulse wave, and the second re-
cording the femoral pulse wave, both with simultan-
eous ECG, for synchronization of carotid and femoral
pulse wave times. Transit time between carotid and
femoral pressure waves was calculated using the foot-
to-foot method. Wave “foots” were identified using the
intersecting tangents algorithm. Two distances on the
Table 1 Epidemiological and clinical characteristics of 81
HD patients
Age (years) 59.8 ± 15.7
Male 52 (64.2)
Dialysis duration (months) 66.2 ± 53.9
Diabetes mellitus 17 (21)
Hypertension 57 (70.4)




Anti-HPTH treatment 46 (56.8)
ESA 73 (90,1)
Intravenous iron 73 (90,1)
BMI (kg/m2) 24.6 ± 4.1
SAP (mmHg) 136.1 ± 18.9
DAP (mmHg) 83.6 ± 12.1
PP (mmHg) 52.9 ± 13.8
MAP (mmHg) 100.9 ± 13.4
Values are expressed as mean±SD or numbers (%) as appropriate.
CVD cardiovascular disease, DAP diastolic arterial pressure, ESA erythropoiesis
stimulating agent, HPTH hyperparathyroidism, MAP mean arterial pressure, PP
pulse pressure, SAP systolic arterial pressure.
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notch to the femoral location and from sternal notch
to the carotid location of the respective pulse wave re-
cording sites. On entering the data into the computer,
travelled distance was calculated automatically as the
difference between the two distances, that is, femoral
location-sternal notch minus sternal notch-carotid lo-
cation. cfPWV results were expressed in meters per
second (m/s) ± SD [13]. Measurements were consid-
ered reliable if the SD was ≤ 15% of the velocity value.
The mean of three such measurements was considered
in the analysis. In two cases cfPWV could not be reli-
ably measured due to atrial fibrillation and impalpable
femoral pulse.
IMT measurements
Ultrasonographic studies were performed with an Aloka®
Prosound A6 instrument (Aloka®, Tokyo, Japan), using a
10 MHz high-resolution probe. Each subject was exam-
ined in the supine position in a semi-dark room during
a mid-week non-dialysis day within one month from
blood sampling. The common carotid artery was investi-
gated bilaterally by the same trained operator, who was
unaware of the patients’ clinical and laboratory parame-
ters. Longitudinal 2D images of the vessel were acquired,
frozen in diastole and analysed offline. ccIMT was calcu-
lated as the distance between the leading edge of the
lumen–intima interface and the media–adventitia inter-
face on the far wall of the artery [14]. Measurements
were performed 0.5, 1 and 2 cm below the carotid bifur-
cation (six measurements, three on each side) in a
plaque-free arterial segment. The average measurement
of the obtained values was taken as ccIMT and it was
considered in the analysis.
Blood pressure measurements
Blood pressure was recorded with an upper arm mer-
cury sphygmomanometer according to the recommenda-
tions of the American Heart Association [15], before the
cfPWV measurement. The mean value in mmHg of
three measurements of systolic arterial pressure (SAP)
and diastolic arterial pressure (DAP) was entered in the
analysis. Pulse pressure (PP) was calculated as the differ-
ence between SAP and DAP, and mean arterial pressure
(MAP) was calculated as [SAP + (2 × DAP)] / 3. Hyper-
tension was defined as systolic blood pressure >140mmHg
and/or diastolic >90mmHg or the current use of anti-
hypertensive medication.
Statistical analysis
Data are expressed as mean ± SD, median with range, or
number of patients with percentage as appropriate. The
associations between fetuin-A, OPG, cfPWV, ccIMT,
and demographic, clinical and laboratory parameterswere assessed. Normality of distribution of continuous
variables was tested by the one sample Kolmogorov-
Smirnov test. Non-normally distributed variables were
log-transformed before entering the analysis. The signifi-
cance of differences between groups was assessed by the
independent samples t-test. Associations between con-
tinuous variables were tested by Pearson’s bivariate and
partial correlation analyses. Multiple linear regression
analysis, with simultaneous inclusion of values into the
model, was used to assess the adjusted combined influ-
ence of variables on the dependent variables (cfPWV or
ccIMT). Variables with p < 0.1 on bivariate analyses or
the independent samples t-test were entered into the
multiple regression models. Despite the significant bi-
variate correlation of SAP and PP with cfPWV, and DP
and MAP with ccIMT, only PP and MAP respectively
were entered in the relevant multiple regression models,
in order to avoid co-linearity. The calculations were
performed using SPSS for Windows® version 13.0 statis-
tical software (SPSS®, Chicago, IL, USA). A two-tailed
p value <0.05 was considered statistically significant.Results
The patients’ epidemiological and clinical character-
istics and laboratory parameters are summarized in
Tables 1 and 2.
Table 2 Laboratory parameters of 81 HD patients
Kt/V 1.46 ±0.21
Hb (g/dl) 11.3 ± 1.2
Creatinine (mg/dl) 9.3 ± 2.1
Calcium (mg/dl) 8.7 ± 0.7
Phosphorus (mg/dl) 5.2 ± 1.4
Ca x P (mg2/dl2) 46.4 ± 13.1
iPTH (pg/dl) 359 ± 276
APL (IU/L) 94 ± 39.8
Albumin (g/dl) 4.0 ± 0.3
Total cholesterol (mg/dl) 150.2 ± 38.5
HDL (mg/dl) 44.9 ± 14.1
LDL (mg/dl) 73.8 ± 31.7
Triglycerides (mg/dl) 139.7 ± 63.6
CRP (mg/L) 7.2 ± 9.3
OPG (pmol/L) 18.498 ± 8.198
Fetuin-A (g/L) 0.713 ± 0.147
cfPWV (m/s) 9.91 ± 2.29
ccIMT (mm) 0.833 ± 0.166
Values are expressed as mean±SD.
ALP alkaline phosphatase, cfPWV carotid to femoral pulse wave velocity, CRP
C-reactive protein, ccIMT common carotid intima–media thickness, HDL high
density lipoprotein, iPTH intact parathormone, LDL low density lipoprotein,
OPG osteoprotegerin.
Table 3 Variables associated with cfPWV, in univariate
and multiple regression analysis
Variable Univariate Multiple regression (**)
p(*) p standard β
Gender 0.973 0.150 −0.128
Age <0.001 0.018 0.267
Diabetes mellitus 0.039 0.063 0.154
History of CVD 0.003 0.220 0.107
Hypertension 0.024 0.052 0.166
SAP 0.006 not entered
PP <0.001 0.010 0.240
LDL 0.037 0.032 0.183
logCRP 0.051 0.481 0.063
Fetuin-A 0.001 0.032 −0.197
OPG <0.001 0.041 0.227
(*)Pearson’s correlation for linear association of continuous variables, and
independent samples t-test for difference between groups, (**)Model adjusted
R2=0.549, p<0.001. cfPWVcarotid-femoral pulse wave velocity, CRP C-reactive
protein, CVD cardiovascular disease, LDL low density lipoprotein, OPG
osteoprotegerin, PP pulse pressure, SAP systolic arterial pressure.
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Fetuin-A correlated negatively with age (r=−0.308,
p=0.005), and logCRP (r=−0.365, p=0.001), and posi-
tively with albumin (r=0.243, p=0.029) and smoking
habit (p=0.039, 95%CI −0.142 to −0.004).
OPG correlated positively with age (r=0.677, p<0.001),
dialysis duration (r=0.225, p=0.046), SAP (r=0.234,
p=0.038) and PP (r=0.339, p=0.002), and negatively with
BMI (r=−0.32, p=0.004) and albumin (r=−0.263, p=0.019).
There was a non-significant negative association be-
tween fetuin-A and OPG levels (r=−0.175, p=0.123).
Correlations of cfPWV with clinical and laboratory
parameters, fetuin-A and OPG levels
Arterial stiffness was associated with history of cardiovas-
cular disease (CVD) (p=0.003, 95% CI=−2.57 to −0.55),
hypertension (p=0.024, 95% CI=−2.37 to −0.17) and dia-
betes mellitus (p=0.039, 95% CI=−2.62 to −0.07), and cor-
related positively with age (r=0.589, p<0.001), SAP
(r=0.306, p=0.006), PP (r=0.403, p<0.001), and LDL levels
(r=0.242, p=0.037) (Table 3).
Arterial stiffness also showed a significant negative cor-
relation fetuin-A levels (r=−0.355, p=0.001) (Figure 1a),
and a strong positive correlation with OPG levels
(r=0.584, p<0.001) (Figure 1b). In partial correlation ana-
lysis these associations were independent of age, gender,
dialysis duration, SAP, PP, LDL levels and co-morbidities,such as diabetes mellitus, hypertension and history of
CVD.
In diabetic patients (n=17, 21%) the correlations of
cfPWV with both fetuin-A and OPG did not reach stat-
istical significance (p=0.173 and p=0.177 respectively)
(Figure 2a and 2b), while in non-diabetic patients (n=64,
79%) the above correlations were highly significant
(p=0.007 and p<0.001 respectively) (Figure 2c and 2d).
In a multiple regression model including age, gender,
diabetes mellitus, history of CVD, hypertension, PP,
LDL, logCRP, both fetuin-A and OPG retained their sig-
nificant association with cfPWV (p=0.032 and p=0.041
respectively), along with age, PP and LDL (Table 3).
Correlations of ccIMT with clinical and laboratory
parameters, fetuin-a and OPG levels
ccIMT was associated with the presence of diabetes
mellitus (p=0.005, 95% CI=−0.21 to −0.04) and history
of CVD (p=0.001, 95% CI=−0.19 to −0.05), and corre-
lated significantly with age (r=0.744, p<0.001), DAP
(r=-0.299, p=0.008), MAP (r=-0.238, p=0.032), serum
albumin (r=−0.293, p=0.008) and logCRP (r=0.285,
p=0.01) (Table 4).
ccMT also showed a significant negative correlation
with fetuin-A levels (r=−0.312, p=0.005) (Figure 1c), and
a strong positive correlation with OPG levels (r=0.521,
p<0.001) (Figure 1d). In partial correlation analysis these
associations were independent of gender, dialysis dur-
ation, DAP, MAP, diabetes mellitus, history of CVD, and
logCRP, but lost significance after adjustment for age.
In diabetic patients (n=17, 21%) the correlations of
ccIMT with fetuin-A and OPG did not reach statistical
Figure 1 Correlations between cfPWV and ccIMT and fetuin-A (1a and 1c respectively) and OPG (1b and 1d respectively) in chronic
HD patients.
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and 3b) whereas in non-diabetic patients (n=64, 79%)
these associations were significant (p=0.024 and p<0.001
respectively) (Figure 3c and 3d).
In multiple regression analysis only age, gender, dia-
betes mellitus and history of CVD were independently
associated with ccIMT (Table 4). In a multiple regression
model including only laboratory parameters (albumin,
logCRP, fetuin-A and OPG, adjusted r2=0.305, p<0.001),
OPG was the only variable significantly correlated with
ccIMT (p<0.001, standard β=0.452).
Discussion
Fetuin-A is a potent systemic inhibitor of calcium phos-
phate precipitation, that binds hydroxyapatite structures,
thus protecting VSMCs from the effects of calcium over-
load and calcification [16]. Recent studies have shown
that serum fetuin-A levels are lower in elderly HD pa-
tients compared with controls [17] and are inversely cor-
related with valvular calcification [18]. Moreover, lower
fetuin-A levels were found to be associated with in-
creased vascular calcification evaluated by computed
tomography (CT) in young HD patients [12] and in eld-
erly community dwellers free of prevalent CVD [19].
However, a recent study in prevalent adult HD patients[20] failed to show any correlation between fetuin-A
levels and coronary artery and abdominal aortic calcifi-
cation scores evaluated by CT scans.
Fetuin-A mediated prevention of VSMC calcification
could potentially attenuate hemodynamic consequences
of vascular calcification, such as arterial stiffening and
increased PWV [16]. In the present study in chronic HD
patients, serum fetuin-A levels were independently asso-
ciated with cfPWV. The results of previous studies
which investigated the above association are inconsist-
ent. Mori et al. [21] found an independent positive cor-
relation between fetuin-A and common carotid artery
stiffness, in healthy Japanese subjects, while Roos et al.
[22] reported an inverse association with aortic PWV in
men, but not in women, with normal renal function. Re-
garding CKD patients, no association between cfPWV
and fetuin-A was found by Schlieper et al. [23] in HD
patients and by Porażko et al. [24] in peritoneal dialysis
and pre-dialysis ESRD patients. Moreover, Hermans
et al. [25] demonstrated, in HD patients, a significant in-
verse correlation, which, however, lost significance after
adjustment for age, gender, MAP and diabetes mellitus.
It should be noted that in the latter study, patients had
fetuin-A levels comparable with controls and low levels
of inflammatory activity. Finally, the studies by Schroff
Figure 2 Correlations between cfPWV and fetuin-A and OPG in diabetic (2a and 2b respectively) and non-diabetic (2c and 2d
respectively) chronic HD patients.
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HD patients, are in agreement with our findings. The
above discrepant results may, at least partially, reflect
differences in methodology and patient population. How-
ever, the independent negative association of cfPWV withTable 4 Variables associated with ccIMT, in univariate
and multiple regression analysis
Variable Univariate Multiple regression (**)
p(*) p standard β
Gender 0.058 0.025 −0.163
Age <0.001 <0.001 0.581
Diabetes mellitus 0.005 0.032 0.154
CVD 0.001 0.046 0.158
DAP 0.008 not entered
MAP 0.032 0.117 −0.124
Albumin 0.008 0.357 0.075
logCRP 0.010 0.875 0.013
Fetuin-A 0.001 0.201 −0.103
OPG <0.001 0.389 0.086
(*)Pearson’s correlation for linear association of continuous variables and
independent samples t-test for difference between groups. (**)Model adjusted
R2=0.615, p<0.001.
ccIMT common carotid intima-media thickness, CRP C-reactive protein, CVD
cardiovascular disease, DAP diastolic arterial pressure, MAP mean arterial
pressure, OPG osteoprotegerin.fetuin-A is in accordance with its well documented anti-
calcifying effects [6,7,16], and its reported negative associ-
ation with mortality [8].
In the present study, fetuin-A also showed a significant
negative association with ccIMT, which however, lost
significance after adjustment for age. Studies investigat-
ing the above association are limited and the results are
inconsistent. A recent study in patients with essential
hypertension and normal renal function showed an inde-
pendent negative correlation of fetuin-A with carotid
IMT [26]. However, an earlier study in community-living
individuals without prevalent CVD failed to demonstrate
a similar association [19], while in 90 patients with ca-
rotid or femoral atherosclerosis and preserved renal
function a positive correlation was observed [27]. Caglar
et al. showed a negative correlation of fetuin-A with ca-
rotid IMT in non-diabetic patients with CKD stage 1–5
which, however, lost significance in multivariate analysis
[28]. Another study reported that lower fetuin-A levels
independently predicted higher carotid IMT in children
and adolescents with ESRD, but not with CKD stages
2–4 [29]. In HD patients, one study found no correlation
[23], and in another the correlation lost statistical sig-
nificance after adjustment for age [30], as in the
present report. However in a study by Pertosa et al. [31]
baseline fetuin-A levels were inversely and independently
Figure 3 Correlations between ccIMT and fetuin-A and OPG in diabetic (3a and 3b respectively) and non-diabetic (3c and 3d
respectively) chronic HD patients.
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later. Differences in methodology and patient population
may again, at least partially, account for the discrepant re-
sults. Furthermore, in contrast to the well documented
anti-calcifying effects of fetuin-A, its association with early
atherosclerotic vascular changes appears to warrant fur-
ther investigation. However, it should be noted that an as-
sociation was reported between fetuin-A and endothelial
dysfunction. Caglar et al. [32] demonstrated an independ-
ent positive correlation between fetuin-A levels and bra-
chial artery endothelium-dependent vasodilatation (FMD),
both before and after renal transplantation. In addition,
another study in non-diabetic patients with CKD stage
1–5 demonstrated that endothelial dysfunction wors-
ened in parallel to the reduction in the estimated
glomerular filtration rate and it was independently as-
sociated with serum fetuin-A levels [28]. Nevertheless,
in prevalent HD patients lower fetuin-A levels have
been associated with increased risk for vascular com-
plications such as loss of arteriovenous access patency
[33] and stroke [34].
Fetuin-A is a negative acute phase reactant and its as-
sociations with cardiovascular morbidity and mortality
might be influenced by the presence of inflammation, a
well recognised risk factor for atherosclerosis and car-
diovascular events [35]. In our study, fetuin-A levels
were negatively correlated with CRP, while the latter was
positively correlated with ccIMT, although the latterassociation lost significance in multivariate analysis. Fur-
thermore, fetuin-A has been associated with insulin re-
sistance [36] and metabolic syndrome [37], and the
presence of diabetes might also influence the associa-
tions between fetuin-A and cardiovascular risk. It should
be noted that a recent prospective study in community-
living individuals older than 65 years and free of CVD
showed that higher fetuin-A levels were associated with
lower CVD risk only among persons without type 2 dia-
betes, whereas a trend in the opposite direction, al-
though non significant, was observed among diabetic
individuals. Moreover, among individuals without type 2
diabetes, similar effect modification was observed by
obesity and insulin resistance [38]. In our study, the cor-
relations of fetuin-A with both cfPWV and ccIMT were
significant only in the non-diabetic patients although a
trend in the same direction was also observed in the dia-
betics. However it should be noted that the number of
diabetic patients was small and studies in larger patient
numbers are needed to confirm these findings.
OPG is produced by osteoblasts as well as by endothe-
lial cells and VSMCs [9]. Its anti-osteoclastic properties
argue for a potential role in bone-vascular crosstalk af-
fecting vascular calcification [16] although the exact
underlying mechanisms remain largely unknown. OPG
concentrations in serum from CKD patients were found
to be independently associated with the serum potential
to induce calcification of smooth muscle cells in vitro
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ently associated with cervical artery calcification in non-
dialysis CKD patients [9] and with moderate coronary
artery calcification in patients with type 2 diabetes, with
and without diabetic nephropathy [40]. Studies in HD
patients demonstrated higher serum OPG levels com-
pared with control subjects [17] and a positive associ-
ation of OPG with arterial medial calcification assessed
by plain film radiography of the pelvis [18], with coron-
ary artery calcification score assessed by CT scan both at
baseline and after 1 year [41], as well as with mortality
[11]. On the contrary, results from animal studies sug-
gested a protective role of OPG on the vasculature.
Thus, OPG knockout mice develop vascular calcification
which can be prevented by injection of transgenic OPG
[42]. Moreover, OPG administration in rats was found to
inhibit artery calcification induced by warfarin and by
vitamin D [43]. The above experimental studies indicate
that the positive association of OPG with vascular calci-
fication in humans may not be necessarily causative, and
it remains unclear whether increased OPG levels pro-
mote arteriosclerosis, or merely represent a compensa-
tory mechanism aiming to attenuate further vascular
injury [16,44].
In the present study an independent association was
observed between cfPWV and OPG. There are few rele-
vant published studies in dialysis patients and their re-
sults appear again inconsistent. A previous study in
adult HD patients failed to document any association
[23], and in another, in children on HD, the association
was confounded by age [12]. However, two other studies,
in accordance with our findings, demonstrated an inde-
pendent association between cfPWV and OPG [10,45].
We also documented a positive association of ccIMT
with OPG, even though it was not independent of age,
which appeared, as expected, the strongest predictor of
ccIMT. Previous studies have shown an independent
positive association between OPG and carotid IMT in
non-renal patients, such as healthy post-menopausal
women [46], women with previous gestational diabetes
[47], subjects older than 55 [48], and males with type 2
diabetes [49], but not patients with acute or chronic cor-
onary artery disease [50]. In a recent study Janda et al.
demonstrated an independent positive association of
OPG with carotid IMT in 61 peritoneal dialysis patients
[51]. To the best of our knowledge, no significant correl-
ation of OPG with ccIMT has been documented in HD
patients. In the present study, using a multiple regres-
sion model that included only laboratory parameters as-
sociated with ccIMT (albumin, CRP, fetuin-A and OPG),
OPG was the only variable that was independently asso-
ciated with ccIMT. This finding, which is in accordance
with the previously reported correlation between OPG
and vascular calcification and mortality, providesadditional support on its association with early athero-
sclerosis, and might indicate a clinically relevant effect
of OPG on endothelial integrity. Finally, it should be
noted that in our study, OPG levels were significantly
associated with both cfPWV and ccIMT only in non-
diabetic patients. However, given the small number of
diabetics further studies are needed to investigate the
above associations in this patient population.
There are some limitations of the present study that
should be considered. It is cross-sectional, which pre-
cludes validation of causative associations, and from a
single centre, which affects generalizability of the results.
Conclusion
Although in the present study, a clear distinction between
arterial stiffness and atherosclerosis cannot be made, our
results suggest that in stable chronic hemodialysis patients
serum levels of the calcification inhibitor fetuin-A and the
osteoclast inhibitor osteoprotegerin are independently as-
sociated with pulse wave velocity, a marker of arterial stiff-
ness but not with carotid intima-media thickness, a
marker of early atherosclerosis.
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